CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Barry Quart

Chief Executive Officer, Connect Biopharma

Search every verified Barry Quart interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Barry Quart, CEO of Connect Biopharma, discussed the company’s recent activities and regulatory strategy in a June ​2025 podcast interview. He noted that Connect Biopharma has initiated two Phase 2 trials for its lead biologic candidate, targeting acute asthma and COPD exacerbations, with goals of improving airway function, reducing hospitalizations, and shortening hospital stays. Quart emphasized the company’s approach of adding its drug to standard of care, arguing that this is the most expedient path to approval and adoption, as medical practice does not change quickly. He also stated that the company has a financial runway into ​2027, allowing it to focus on execution rather than immediate financing. Quart also shared perspectives on working with the FDA, drawing on his experience in regulatory affairs at BMS and Pfizer. He advised that the agency generally provides guidance rather than clear instructions, and stressed the importance of asking comprehensive questions during meetings such as pre‑IND or end‑of‑Phase 2, as these are opportunities to receive timely written responses. Additionally, he discussed Connect Biopharma’s relocation from China to San Diego, noting that a U.S. financial reporting structure helps attract investors.

Recent appearances

  • This Biotech CEO Is Helping Fight Asthma. Meet Barry Quart CEO Connect Biopharma $CNTB

    May 20, 2026 · 📺 Smart Money Circle Show Hosted By Adam Sarhan

    Guest: Barry Quart, CEO and Director Company: Connect Biopharma, NASDAQ:CNTB Website: https://www.connectbiopharma.com/ Connect Biopharma Bio: Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. C…

    Watch on YouTube ↗

  • Episode 130 - Barry Quart - CEO Connect Biopharma

    March 16, 2026 · 📺 The Biohub

    In this episode of The BioHub Podcast, Max sits down with Barry Quart, CEO of Connect Biopharma and one of the most experienced biotech leaders in the industry. Barry’s career spans more than three decades across biotech and pharma, including founding Ardea Biosciences (acquired by AstraZeneca) and leading Heron Therapeutics, where he helped bring multiple drugs through development and approval. Across his career he has played a role in nine FDA-approved medicines. In this conversation, Barry shares the lessons he’s learned building biotech companies, what it really takes to develop succes…

    Watch on YouTube ↗

  • Connect Biopharma CEO Barry Quart: Targeting a $5B+ Market with a Next-Gen Asthma & COPD Therapy

    November 07, 2025 · 📺 RedChip Companies

    🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes. In this exclusive RedChip interview, CEO Dr. Barry Quart discusses: ✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety. ✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies. ✅ Key upcoming catalysts: topline data from P…

    Watch on YouTube ↗

  • Connect Biopharma (Nasdaq: CNTB) Investor Webinar - November 3, 2025

    November 04, 2025 · 📺 RedChip Companies

    Join RedChip and Connect Biopharma (Nasdaq: CNTB) CEO Barry Quart for an in-depth investor update on rademikibart, a next-generation anti-IL-4Rα antibody being advanced for acute exacerbations in asthma and COPD, with a path toward chronic treatment. This presentation outlines the company’s U.S. transformation, late-stage clinical progress, and upcoming catalysts driving the Connect 2.0 strategy. 🔍 What You’ll Learn • Clinical Focus: Two Phase 2 trials in acute asthma and acute COPD patients experiencing exacerbations—an area with no approved biologic therapies. • Why It Matters: Rapid onset…

    Watch on YouTube ↗

  • FDA Trials And Tribulations With Connect Biopharma's Barry Quart

    June 22, 2025 · 📺 Life Science Connect

    On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations. This episode of the Business of Biotech is brought to you by Ecolab Life Sciences. Lea…

    Watch on YouTube ↗

  • Interview with Connect Biopharma CEO Barry Quart | Transforming Acute Asthma & COPD Care

    April 04, 2025 · 📺 RedChip Companies

    Connect Biopharma Holdings Ltd. (Nasdaq: CNTB) is a clinical-stage biotechnology company advancing innovative therapeutics designed to transform the treatment landscape for inflammatory diseases driven by T-cell dysfunction. The company’s lead candidate, rademikibart, is a next-generation, highly differentiated monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), with potential applications in asthma and chronic obstructive pulmonary disease (COPD)—markets collectively representing multi-billion-dollar commercial opportunities. Backed by robust clinical data from a global Phase…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →